NCT06221462View on ClinicalTrials.gov

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

February 1, 2030

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Sintilimab

200mg, every 3 weeks, 3 cycles, in the neoadjuvant setting, and adjuvant 200mg,every 3 weeks no more than one year

DRUG

Anlotinib

8mg, orally, D1-14, every 3 weeks, 2 cycles in only neoadjuvant setting

All Listed Sponsors
lead

Ningbo No.2 Hospital

OTHER